[go: up one dir, main page]

EP1505991A1 - Combinaison de medicaments contre le virus de la grippe - Google Patents

Combinaison de medicaments contre le virus de la grippe

Info

Publication number
EP1505991A1
EP1505991A1 EP02800058A EP02800058A EP1505991A1 EP 1505991 A1 EP1505991 A1 EP 1505991A1 EP 02800058 A EP02800058 A EP 02800058A EP 02800058 A EP02800058 A EP 02800058A EP 1505991 A1 EP1505991 A1 EP 1505991A1
Authority
EP
European Patent Office
Prior art keywords
ribavirin
nac
influenza virus
association
against influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02800058A
Other languages
German (de)
English (en)
Inventor
Domenico Ungheri
Giovanni Battista Colombo
Luciano Licciardello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zambon SpA
Original Assignee
Zambon Group SpA
Zambon SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Group SpA, Zambon SpA filed Critical Zambon Group SpA
Publication of EP1505991A1 publication Critical patent/EP1505991A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom

Definitions

  • NAC can increase significatively and in a synergistic manner the antiviral activity of Ribavirin.
  • Object of the present invention therefore is a pharmaceutical composition containing NAC and Ribavirin to antagonise flu virus by increasing Ribavirin efficacy.
  • a second object of the present invention is the use of NAC for preparing pharmaceutical compositions to administer in combined therapy with Ribavirin to antagonise flu virus.
  • NAC and Ribavirin or multiples thereof, in a form for administration are provided.
  • compositions object of the invention are preferably those suitable by oral administration (tablets, capsules, syrups, water-soluble forms), by aerosol (especially ready or extemporaneous solutions to be administered by suitable inhalers) or by injective route (ready solutions or to be prepared at the moment of use from lyophilized).
  • Example 1 Effect of NAC and Ribavirin association on the lethality of flu virus in mice
  • the animals were infected intranasally with a viral flu suspension (strain PR/8, suspension in 0.05 ml of culture medium) in a dose of 2-3 LD 50 and therefore they were randomly assigned (12 animals each group) to the following groups:
  • Group 2 treated with Ribavirin 100 mg/kg i.p.
  • Group 3 treated with NAC 1000 mg/kg p.o.
  • Example 3 A kit containing Ribavirin in injectable solution (1200 mg) and effervescent tablets of NAC (2x600 mg, FLUIMUCIL ® ) was prepared.
  • the kit contains the instructions for use and a sterilized syringe for i.v. injection of Ribavirin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une combinaison de médicaments contre le virus de la grippe et plus particulièrement l'association de la N-acétyl-cystéine et de la ribavirine et l'utilisation de cette combinaison pour le traitement de la maladie provoquée par le virus de la grippe.
EP02800058A 2001-09-05 2002-08-01 Combinaison de medicaments contre le virus de la grippe Withdrawn EP1505991A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2001MI001863A ITMI20011863A1 (it) 2001-09-05 2001-09-05 Associazione di farmaci contro il virus dell'influenza
ITMI20011863 2001-09-05
PCT/EP2002/008584 WO2003028717A1 (fr) 2001-09-05 2002-08-01 Combinaison de medicaments contre le virus de la grippe

Publications (1)

Publication Number Publication Date
EP1505991A1 true EP1505991A1 (fr) 2005-02-16

Family

ID=11448332

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02800058A Withdrawn EP1505991A1 (fr) 2001-09-05 2002-08-01 Combinaison de medicaments contre le virus de la grippe

Country Status (3)

Country Link
EP (1) EP1505991A1 (fr)
IT (1) ITMI20011863A1 (fr)
WO (1) WO2003028717A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021217221A1 (fr) * 2020-05-01 2021-11-04 MUCPharm Pty Ltd Prévention et traitement d'infections virales

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339256C (fr) * 1989-01-26 1997-08-12 Wulf Droge Traitement de maladies associees aux infections par le vih
US5580577A (en) * 1990-01-11 1996-12-03 Herzenberg; Leonard A. Method of treating the symptoms of human rhinovirus infection
ATE444760T1 (de) * 1997-01-13 2009-10-15 Univ Emory Glutathion zur behandlung von influenzainfektionen
AR023541A1 (es) * 1999-04-19 2002-09-04 Schering Corp Terapia de combinacion para vhc

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03028717A1 *

Also Published As

Publication number Publication date
WO2003028717A1 (fr) 2003-04-10
ITMI20011863A0 (it) 2001-09-05
ITMI20011863A1 (it) 2003-03-05

Similar Documents

Publication Publication Date Title
US9387227B2 (en) Method for treatment of sores and lesions of the skin
ES2988617T3 (es) Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales
US20090304630A1 (en) Treating severe and acute viral infections
EA037085B1 (ru) Композиция для устранения заложенности носа, обладающая противовирусным действием
JPH06505231A (ja) 癌またはエイズの治療におけるキノンの使用
Sidwell et al. Inhibitory effects of recombinant manganese superoxide dismutase on influenza virus infections in mice
CA2465062C (fr) Agent preventif et/ou therapeutique contre les infections virales
EP1505991A1 (fr) Combinaison de medicaments contre le virus de la grippe
WO2021198940A1 (fr) Composition destinée à prévenir ou soigner une infection virale chronique ou aiguë et/ou une septicémie chez l'être humain ou chez l'animal
EP0576506B1 (fr) Utilisation d'un benzimidazole vermifuge dans le traitement des infections par microsporides
CN114762694B (zh) 寡糖转移酶抑制剂在预防和/或治疗新型冠状病毒感染中的应用
CN102805866B (zh) 一种兽用药物制剂及其应用
CN1432357A (zh) 包含木糖醇的解热制剂
CN107648249B (zh) 去半乳糖替告皂甙在制备防治流感病毒感染的药物中的应用
JP2006008540A (ja) 風邪薬
RU2103997C1 (ru) Лекарственное средство для лечения заболеваний животных микробной этиологии, способ лечения желудочно-кишечных заболеваний животных микробной этиологии и способы лечения гинекологических заболеваний коров микробной этиологии
CN117298149A (zh) 铟掺杂的硫磷化铜量子点在抑制冠状病毒的应用
RU2146147C1 (ru) Антипаразитарный препарат пролонгированного действия
US4073928A (en) Therapeutic treatment for viral regional ileitis infection
RU2223755C1 (ru) Способ лечения рецидивирующего иридоциклохориоидита лошадей
CN1195520C (zh) 畜禽用一种新型的复方抗菌消炎药
WO2024005747A1 (fr) Spray nasal antiviral
US20240269222A1 (en) Composition for respiratory diseases
CN120114429A (zh) Ndna或其药学上可接受的盐和trpm4-in-1或其药学上可接受的盐联用的用途
RU2024123662A (ru) Фармацевтический агент для лечения новой коронавирусной инфекции

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040405

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ZAMBON S.P.A.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100302